NRC Quote, Financials, Valuation and Earnings

DarioHealth Corp. has a net margin of 11.54% compared to National Research Corp.'s net margin of -41.48%. National Research Corp.'s return on equity of 61.55% beat DarioHealth Corp.'s return on equity of -41.55%.

National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 51.45%. Given that DarioHealth Corp. has higher upside potential than National Research Corp., analysts believe DarioHealth Corp. is more attractive than National Research Corp..

National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.

National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.94%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

National Research Corp. quarterly revenues are $34.6M, which are larger than DarioHealth Corp. quarterly revenues of $5M. National Research Corp.'s net income of $4M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, National Research Corp.'s price-to-earnings ratio is 23.16x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 2.67x versus 6.69x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GoodRx Holdings, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of 0.57%. National Research Corp.'s return on equity of 61.55% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $5.09 which suggests that it could grow by 85.07%. Given that GoodRx Holdings, Inc. has higher upside potential than National Research Corp., analysts believe GoodRx Holdings, Inc. is more attractive than National Research Corp..

National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.94%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

National Research Corp. quarterly revenues are $34.6M, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. National Research Corp.'s net income of $4M is higher than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, National Research Corp.'s price-to-earnings ratio is 23.16x while GoodRx Holdings, Inc.'s PE ratio is 32.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 2.67x versus 1.26x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of -2156852.78%. National Research Corp.'s return on equity of 61.55% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 721.92%. Given that Predictive Oncology, Inc. has higher upside potential than National Research Corp., analysts believe Predictive Oncology, Inc. is more attractive than National Research Corp..

National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.94%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

National Research Corp. quarterly revenues are $34.6M, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. National Research Corp.'s net income of $4M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, National Research Corp.'s price-to-earnings ratio is 23.16x while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 2.67x versus 16.78x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of 9.46%. National Research Corp.'s return on equity of 61.55% beat Spok Holdings, Inc.'s return on equity of 10.88%.

National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.17%. Given that Spok Holdings, Inc. has higher upside potential than National Research Corp., analysts believe Spok Holdings, Inc. is more attractive than National Research Corp..

National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.94%. Spok Holdings, Inc. offers a yield of 9.59% to investors and pays a quarterly dividend of $0.31 per share. National Research Corp. pays 45.99% of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Spok Holdings, Inc.'s is not.

National Research Corp. quarterly revenues are $34.6M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. National Research Corp.'s net income of $4M is higher than Spok Holdings, Inc.'s net income of $3.2M. Notably, National Research Corp.'s price-to-earnings ratio is 23.16x while Spok Holdings, Inc.'s PE ratio is 16.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 2.67x versus 1.94x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.